SEARCH

SEARCH BY CITATION

References

  • 1
    Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013; 380: 20952128.
  • 2
    Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD, Murray CJ. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. Lancet. 2013; 380: 21442162.
  • 3
    World Population Prospects, the 2010 Revision [Internet database]. New York: The United Nations. c20102011—[accessed 2012 Jul 16]. Available from: http://esa.un.org/wpp/Excel-Data/mortality.htm.
  • 4
    Hegde S, Schmidt M, Gaudillière B, Galatsis P, Cheng X, Strupczewski JD, Ong HH, Allen RC, Ellis DB, Berna P, et al. To market, to market. In: Macor J, Wood A, Doherty A, Bristol J, eds. Annual Reports in Medicinal Chemistry. 27th–46th edn. New York: Academic Press; 19922011.
  • 5
    Paul S, Mytelka D, Dunwiddie C, Persinger C, Munos B, Lindborg S, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discovery. 2010; 9: 0314.
  • 6
    PhRMA. Pharmaceutical industry profile 2011. Washington, DC: Pharmaceutical Research and Manufacturers of America; 2011.
  • 7
    Light DW, Warburton RN. Extraordinary claims require extraordinary evidence. J Health Econ. 2005; 24: 10301033.
  • 8
    Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 345: 2225.
  • 9
    World Economic Outlook [Internet database]. Washington, DC: The International Monetary Fund. c2012—[accessed 2012 Jul 16]. Available from: http://www.imf.org/external/pubs/ft/weo/2012/01/weodata/index.aspx.
  • 10
    World Development Indicators & Global Development Finance [Internet database]. Washington, DC: The World Bank. c2012—[accessed 2012 Jul 5]. Available from: http://databank.worldbank.org/ddp/home.do?Step=1&id=4.
  • 11
    Guterl F. The World's Best Countries in Science: SA's Global Science Scorecard. Sci Am. 2012; 307: 4445.
  • 12
    Gura T. US medical researchers brace themselves for budget cuts. Lancet. 2012; 380: 13711372.
  • 13
    Catanzaro M. Spain reeling from budget and staff cuts in biomedicine. Nat Med. 2012; 18: 184.
  • 14
    Jennings GL, Macmahon S, Donnan GA. Cuts to the NHMRC budget will undermine the health of all Australians—today and in the future. Med J Aust. 2011; 194: 436437.
  • 15
    Kola I. The state of innovation in drug development. Clin Pharmacol Ther. 2008; 83: 227230.
  • 16
    Janero DR. Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca. Expert Opin Drug Discov. 2012; 7: 449456.
  • 17
    Morgan SG, Cunningham CM, Law MR. Drug development: innovation or imitation deficit? BMJ. 2012; 345: 30.
  • 18
    Barden C, Weaver DF. The rise of micropharma. Drug Discovery Today. 2009; 15: 8487.
  • 19
    Kneller R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat Rev Drug Discovery. 2010; 9: 867882.